Sandoz May Turn To Novartis Sales Force For Omnitrope Marketing
This article was originally published in The Pink Sheet Daily
Executive Summary
Sandoz' follow-on human growth hormone cleared FDA May 30, but the agancy asserts that the approval does not create a biosimilar regulatory pathway.